Wire · regulatory
Opinion: FDA must ensure American patients can access new and experimental drugs
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 5 October 2026 · Fusion42 review
The FDA has initiated efforts like Operation TrialBlazer to speed up first-in-human trials but faces pressure to further streamline processes to retain clinical research in the U.S. as China gains ground in biotech trials, risking patient access to experimental treatments and U.S. leadership in drug approval.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You must act quickly to navigate growing FDA reforms aimed at speeding drug trials as American clinical research shifts abroad. This opens chances to engage earlier with U.S. regulators and patient groups before competitors capture this space.
◆ Coverage
1 source · 5 Oct 2026
◆ Related on Wire
◆ Topics